Iradimed Co

IRadimed Corporation reported second-quarter 2026 revenue of $20.5 million, a 0.5% increase from the prior year, and achieved its manufacturing target of 130 to 135 units for the new 3870 MR IV pump system. GAAP diluted earnings per share were $0.41, down from $0.45, while non-GAAP diluted EPS were $0.46, excluding stock-based compensation. Gross margin declined to 74% from 78% due to higher manufacturing costs and inefficiencies during the first production ramp of the 3870 pump. The company plans to more than double 3870 production to over 300 units in the third quarter and reaffirmed full-year 2026 revenue guidance of $91 million to $96 million and non-GAAP EPS guidance of $2.09 to $2.24.

iRadimed has declared a quarterly dividend of $0.20 per share, in line with the previous payout. The dividend is payable on August 28 to shareholders of record as of August 14, with the ex-dividend date also set for August 14. The forward yield stands at 0.88%.

IRadimed anticipates third-quarter revenue of $23 million to $24.5 million as it more than doubles production of its new 3870 MR IV pump system to over 300 units. The company reported second-quarter revenue of $20.5 million, up 0.5% from a year earlier, with gross margin declining to 74% from 78% due to higher manufacturing costs tied to the first sizable production ramp of the 3870. Bookings in the quarter were more than double the units shipped, and 70% of those orders were for the 4-channel quad pump system, which carries an average selling price north of $110,000. Management reaffirmed full-year 2026 revenue guidance of $91 million to $96 million and raised the non-GAAP diluted earnings per share range to $2.09 to $2.24. The company expects start-up costs experienced in the second quarter to be better than 50% reduced in the third quarter, though lead times for new quad orders are extending toward four to six months amid strong demand.

Iradimed Corporation will release its second-quarter fiscal 2026 results before the market opens on July 31, 2026. In the first quarter of fiscal 2026, net revenue rose 12.7% to $21.98 million, driven by growth in MRI-compatible IV infusion pump systems and patient vital signs monitoring systems. Total devices revenue increased to $15.39 million from $12.96 million a year earlier, with IV infusion pump systems revenue reaching $7.66 million and patient vital signs monitoring systems revenue at $7.11 million. Net income attributable to Iradimed grew to $5.82 million, or $0.45 per diluted share, compared with $4.69 million, or $0.37 per share, in the prior-year quarter. For the second quarter, the company expects revenue of $20.0 million to $21.0 million and diluted earnings per share of $0.40 to $0.44, while reaffirming full-year 2026 revenue guidance of $91.0 million to $96.0 million.